Discover how IBL4, a B cell line from an AIDS-related lymphoma, stimulates Vy2Vd2 T cells and could transform cancer immunotherapy approaches.
Discover how engineered oncolytic viruses use bystander T cell epitopes to trigger powerful anti-tumor immune responses and enhance cancer immunotherapy.